Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c.
Aged
Biomarkers
/ blood
Blood Glucose
/ metabolism
Diabetes Mellitus
/ blood
Female
Glucose Tolerance Test
Glycated Hemoglobin
/ metabolism
Humans
Male
Middle Aged
Myocardial Infarction
/ blood
Patient Admission
Prediabetic State
/ blood
Predictive Value of Tests
Prognosis
Registries
Risk Assessment
Risk Factors
Sweden
Time Factors
Diabetes
Hemoglobin A1c
Myocardial infarction
Oral glucose tolerance test
Prediabetes
Prognosis
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
14 06 2021
14 06 2021
Historique:
received:
28
03
2021
accepted:
05
06
2021
entrez:
15
6
2021
pubmed:
16
6
2021
medline:
4
1
2022
Statut:
epublish
Résumé
Disturbances of glucose metabolism can be diagnosed by an oral glucose tolerance test (OGTT) and by glycated haemoglobin (HbA1c). The aim of this study was to investigate the association between newly detected disturbances of glucose metabolism and long-term prognosis after acute myocardial infarction (AMI) and to compare the predictive value of an OGTT and HbA1c. Patients under the age of 80 years with no known history of diabetes admitted for AMI at the Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden, from January 1st, 2006 until December 31st, 2013, were investigated with an OGTT and a HbA1c before discharge and were classified as having normal glucose tolerance (NGT), prediabetes or diabetes according to American Diabetes Association (ADA) criteria. Using nationwide, all-inclusive registers, patients were followed for the incidence of combined event [CE (first of myocardial infarction, heart failure, ischaemic stroke or mortality)] for a mean follow-up time of 4.8 years. Cox regression analysis was used to calculate Hazard Ratios (HR) and their 95% confidence intervals (CI). Of the 841 patients who were investigated with both an OGTT and a HbA1c, 139 (17%) patients had NGT, 398 (47%) had prediabetes and 304 (36%) had diabetes according to OGTT. The corresponding figures using HbA1c were 320 (38%), 461 (55%) and 60 (7%). Patients with newly discovered diabetes were older and had a higher body mass index compared to those with NGT. OGTT was not predictive for CE. In contrast, prediabetes identified by a HbA1c was associated with an increased risk for CE (HR 1.31; 95% CI 1.05-1.63) compared to normoglycaemia. When comparing the prognostic value of different glucose and HbA1c cut-offs, only a HbA1c ≥ 39 mmol/mol was significantly associated with CE (HR 95% CI; 1.30:1.05-1.61). In this single-centre study, in a recent contemporary cohort, we found that around two thirds of the patients admitted with AMI with no known history of diabetes had disturbed glucose metabolism, in accordance with previous studies. HbA1c in the prediabetes range, but not OGTT, added predictive value on the long-term outcome, in a cohort to whom a pathologic OGTT result was communicated with lifestyle advice.
Sections du résumé
BACKGROUND
Disturbances of glucose metabolism can be diagnosed by an oral glucose tolerance test (OGTT) and by glycated haemoglobin (HbA1c). The aim of this study was to investigate the association between newly detected disturbances of glucose metabolism and long-term prognosis after acute myocardial infarction (AMI) and to compare the predictive value of an OGTT and HbA1c.
METHODS
Patients under the age of 80 years with no known history of diabetes admitted for AMI at the Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden, from January 1st, 2006 until December 31st, 2013, were investigated with an OGTT and a HbA1c before discharge and were classified as having normal glucose tolerance (NGT), prediabetes or diabetes according to American Diabetes Association (ADA) criteria. Using nationwide, all-inclusive registers, patients were followed for the incidence of combined event [CE (first of myocardial infarction, heart failure, ischaemic stroke or mortality)] for a mean follow-up time of 4.8 years. Cox regression analysis was used to calculate Hazard Ratios (HR) and their 95% confidence intervals (CI).
RESULTS
Of the 841 patients who were investigated with both an OGTT and a HbA1c, 139 (17%) patients had NGT, 398 (47%) had prediabetes and 304 (36%) had diabetes according to OGTT. The corresponding figures using HbA1c were 320 (38%), 461 (55%) and 60 (7%). Patients with newly discovered diabetes were older and had a higher body mass index compared to those with NGT. OGTT was not predictive for CE. In contrast, prediabetes identified by a HbA1c was associated with an increased risk for CE (HR 1.31; 95% CI 1.05-1.63) compared to normoglycaemia. When comparing the prognostic value of different glucose and HbA1c cut-offs, only a HbA1c ≥ 39 mmol/mol was significantly associated with CE (HR 95% CI; 1.30:1.05-1.61).
CONCLUSION
In this single-centre study, in a recent contemporary cohort, we found that around two thirds of the patients admitted with AMI with no known history of diabetes had disturbed glucose metabolism, in accordance with previous studies. HbA1c in the prediabetes range, but not OGTT, added predictive value on the long-term outcome, in a cohort to whom a pathologic OGTT result was communicated with lifestyle advice.
Identifiants
pubmed: 34126971
doi: 10.1186/s12933-021-01315-5
pii: 10.1186/s12933-021-01315-5
pmc: PMC8204442
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Types de publication
Comparative Study
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
122Références
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):25-32
pubmed: 31722562
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Heart. 2010 Oct;96(20):1617-21
pubmed: 20801780
Eur J Prev Cardiol. 2017 Jun;24(3_suppl):52-60
pubmed: 28618910
Diabetes Care. 2006 Jan;29(1):26-31
pubmed: 16373891
Eur Heart J. 2018 Aug 1;39(29):2740-2745
pubmed: 29701834
Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120973676
pubmed: 33231125
Lancet. 2002 Jun 22;359(9324):2140-4
pubmed: 12090978
Eur Heart J. 2015 May 14;36(19):1171-7
pubmed: 25670820
Clin Endocrinol (Oxf). 2019 Sep;91(3):411-416
pubmed: 31152677
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Diabetologia. 2004 Mar;47(3):385-394
pubmed: 14985967
J Am Coll Cardiol. 1999 Oct;34(4):1348-59
pubmed: 10520820
Heart. 2005 Nov;91(11):1466-8
pubmed: 16230445
Eur Heart J. 2004 Nov;25(22):1990-7
pubmed: 15541834
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Diab Vasc Dis Res. 2015 Jan;12(1):23-32
pubmed: 25311248
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
N Engl J Med. 2010 Mar 4;362(9):800-11
pubmed: 20200384
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Heart. 2007 Jan;93(1):72-7
pubmed: 16905628
Cardiovasc Diabetol. 2020 Dec 5;19(1):204
pubmed: 33278898
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Nat Rev Endocrinol. 2016 Oct;12(10):616-22
pubmed: 27388988
Diabetes Care. 2017 Sep;40(9):1233-1240
pubmed: 28637653
Lancet Diabetes Endocrinol. 2015 Aug;3(8):624-37
pubmed: 26109024